Business Context and Reporting Period
This Form 8-K Current Report from Protagonist Therapeutics, Inc. covers events occurring on December 21, 2018, and December 22, 2018. The company is a biotechnology firm incorporated in Delaware and classified as an emerging growth company.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses on corporate governance and capital structure transactions rather than operational financial performance.
Material Changes and Transactions
- Share Exchange Agreement: On December 21, 2018, the Company entered into an agreement with entities affiliated with Biotechnology Value Fund, L.P. to exchange 1,000,000 shares of common stock for pre-funded warrants (Exchange Warrants) to purchase 1,000,000 shares of common stock.
- Warrant Terms: The Exchange Warrants have an exercise price of $0.00001 per share and expire ten years from issuance. They are subject to a beneficial ownership limitation of 9.99% and do not carry voting rights except as required by Delaware law.
- Regulatory Status: The warrants were issued without registration under the Securities Act of 1933, relying on the Section 3(a)(9) exemption.
Management Changes and Outlook
- CFO Departure: Thomas P. O'Neil voluntarily resigned as Chief Financial Officer, effective January 11, 2019. The resignation is not due to any dispute with the Company.
- Interim Appointments:
- Dinesh V. Patel, Ph.D. (President and CEO), will serve as Interim Principal Financial Officer.
- Niall Murphy (Vice President and Corporate Controller), will serve as Interim Principal Accounting Officer.
- Outlook: The Company will initiate a search for a permanent replacement for the CFO position. No specific financial guidance or operational outlook was provided in this filing.
Investor Verification Checklist
- Verify the impact of the 1,000,000 share exchange on total outstanding shares and potential dilution upon warrant exercise.
- Confirm the timeline and progress of the search for a permanent Chief Financial Officer.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for specific covenants and risk allocation details.
- Monitor future filings for the appointment of a permanent CFO and any changes to the capital structure.